English

FAQs
Important Safety Information
Prescribing Information
Patient Medication Guide
Infusion Center Locator
E-Sign TOUCH^® Enrollment Form
FAQs
Patient Site

Important Safety Info
Prescribing Information
E-Sign TOUCH^® Enrollment Form
Patient Site

Start TYSABRI
Pivotal Trial, Safety, and Efficacy
Additional Studies
- Onset
- CDI
- QoL
- TOP 10
- TOP 15
- Global Safety Study
- NEDA Study
Proposed MOA
- Proposed MOA
REMS: TOUCH® Prescribing Program
- TOUCH On-Line
- iAssist®

Sign Up
My Account
- Edit
  Profile
- Log Out

FAQs
Important Safety Information
Prescribing Information
Patient Medication Guide
Infusion Center Locator
E-Sign TOUCH^® Enrollment Form
FAQs
Patient Site

Official Physician Home page | TYSABRI® (natalizumab) HCP
Register Email
Cookie Policy

AE=adverse event; ARR=annualized relapse rate; CI=confidence interval; DMT=disease-modifying therapy; EDSS=Expanded Disability Status Scale; IV=intravenous; JCV=John Cunningham virus; MedDRA=Medical Dictionary for Regulatory Activities; RRMS=relapsing-remitting multiple sclerosis; SAE=serious adverse event.

References: 1. Trojano M, Wiendl H, Butzkueven H, et al. TYSABRI® Observational Program: Long-term safety and effectiveness in relapsing-remitting multiple sclerosis over 15 years. Poster presented at EAN 9th Congress. 2023; EPO-658. 2. Butzkueven H, Kappos L, Wiendl H, et al; for the TOP Investigators. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the TYSABRI Observational Program (TOP). J Neurol Neurosurg Psychiatry. 2020;91(6):660-668. 3. Butzkueven H, Kappos L, Pellegrini F, et al; TYSABRI Observational Program (TOP) Investigators. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry. 2014;85(11):1190-1197.